Phil Serlin: Yes. So that’s a good question. I mean we — obviously, this is a very significant strengthening of our balance sheet. It provides us on a pro forma basis with over $60 million in cash and puts us in a really good position to continue to execute on our launch and on the rest of our programs without having any significant stress. We have a lot of optionality, I’d have to say, between what we have on our balance sheet and the Kreos Capital loan. And so we feel very comfortable right now going into launch whether we have — we really do have plenty of capital to go forward. We haven’t given the guidance right now because we have — this is so new. We haven’t had a chance to update our forecast. But I believe that this will give us adequate capital way past launch and into the latter half of 2024, if not beyond.
Our current burn rate, I think you asked, is somewhere in the $7.5 million to $10 million per quarter depending right now, we’re in launch mode. We’re in prelaunch mode and there is a lot of very heavy lifting that has to be done. I think it would probably settle out to closer to the $7 million to $8 million range going forward once we’ve completed all the heavy lifting in connection with the launch.
John Vandermosten: Okay, great. Thank you, Phil.
Phil Serlin: No problem.
Operator: There are no further questions at this time. Before I ask Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin two hours after the conference. In the U.S. please call 1 (888) 295-2634. In Israel, please call (03) 925-5904. Internationally, please call 9723-9255-904. Mr. Serlin, would you like to make your concluding statements?
Phil Serlin: Yes. Thank you, operator. In closing, we are progressing through 2023 with significant momentum. We are preparing for the potential U.S. approval of our first therapy in stem cell mobilization and we are ready for commercial launch. We have worked to strengthen our balance sheet through the strategic relationship announced today, made significant advancements in our pancreatic development program and further positioned Motixafortide for development in Asia for stem cell mobilization indications. We have also taken important additional life cycle management steps by entering into a collaboration to execute a clinical trial with the Motixafortide as a mobilization agent in gene therapies. I’m extremely pleased with our progress during the second quarter, and I’m excited about what we are in the process of achieving this year. I want to thank you all very much for your continued interest in BioLineRx. Be safe, and have a great day.
Operator: Thank you. This concludes the BioLineRx Investor Relations Call. Thank you for your participation. You may go ahead and disconnect.
